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Background: Juvenile Idiopathic Arthritis (JIA) commonly affects joints of the lower limb including the knee, ankle,
subtalar and other foot joints. Intra-articular corticosteroid injections (IACIs) are considered to be effective for short-term
relief of synovitis, however, there appears to be a significant lack of published evidence from comparative effectiveness
studies. The aim of this study was to identify and critically appraise the evidence for the efficacy of lower limb IACIs in
children/adolescents with JIA.
Methods: Studies were identified in databases Medline, Embase, CINAHL, AMED, PEDro, the Cochrane Library and
TRIP, with no date restrictions. The primary search terms ‘juvenile idiopathic arthritis’, ‘lower limb’, ‘knee’; ‘ankle’,
‘foot’ and ‘intra-articular steroid injections’ and related synonyms were used to develop a comprehensive
pragmatic literature search strategy. Included studies were quantitative longitudinal design such as randomised
controlled trials, pseudo-randomised and non-randomised experimental studies, cohort studies, and case-control
studies. All outcomes measures were subject to analysis. Quality assessment was conducted using the Cochrane
Collaboration criteria with additional criteria for sample population representativeness, quality of statistical analysis
and compliant intervention use and presence of co-interventions. Qualitative data synthesis was conducted for
the outcome domains. Meta-analyses were not possible as multiple randomised controlled trials for outcome
measures were not available. Levels of evidence were assigned to each outcome measure.
Results: The inclusion criteria were met by twenty-one studies. One study had high quality for internal validity
and nine studies had high quality for external validity. No studies had high quality for both internal and external
validity. Four outcome domains were identified. There was weak evidence for IACIs decreasing clinical signs and
symptoms in the lower leg, improving joint range of motion, decreasing leg length discrepancy, and for imaging
techniques detecting the effects of IACIs.
Conclusions: There is some weak evidence for the efficacy of IACIs improving certain outcome measures.
However, there is also some inconclusive evidence due to a lack of quality studies. More high quality evidence is
necessary to definitely determine the efficacy of IACIs for JIA in the lower leg.
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Juvenile Idiopathic Arthritis (JIA) is the most common
rheumatic disorder in children, affecting approximately 1
in 1000 Australian children [1]. Lower limb arthritis is
common in JIA regardless of disease classification, with
the knee joint affected most frequently at disease onset
(40-60% of cases) followed by the ankle (20-30% of cases)
[2,3]. Persistent synovitis in these joints is associated with
pain, reduced joint ranges of motion, deformities, gait dis-
ruption, and poor functional status [4-7]. Moreover, radio-
graphic progression of the disease occurs early, and if not
addressed may result in permanent joint destruction and
poor functional outcomes [8,9].
The primary aim of medical management in JIA is to
suppress inflammation prior to the development of irrep-
arable joint damage and functional limitation [10]. Recent
improvements in the medical management of JIA have led
to a greater emphasis on early diagnosis of JIA, early de-
tection of synovitis, and subsequent prompt and aggres-
sive systemic medical intervention via disease-modifying
and/or biologic regimens to control the inflammatory dis-
ease process [11]. The introduction of such regimens have
led to a relative increase in the number of patients achiev-
ing disease improvements characterised by low disease ac-
tivity or remission [12]. However, in spite of promising
signs of improvement, children may experience refractory
disease, characterised by continued persistent synovitis,
and/or serious adverse effects including hepato-toxicity and
immuno-deficiency following administration of methotrex-
ate and etanercept [13].
Intra-articular corticosteroid injections (IACIs) are often
used as the main form of management in milder oligoarti-
cular JIA, and also as an adjunct to systemic therapy in
other JIA subtypes where localised synovitis is restricted to
a single or a small number of joints [13,14]. IACIs are ad-
ministered to induce rapid relief of symptoms through
resolution of localised synovitis, and in some cases may
prevent the need for escalation of systemic therapy and as-
sociated increased risk of serious side-effects [14]. It is ac-
knowledged that IACIs are also associated with adverse
events, however, these may be relatively mild compared to
those associated with systemic disease-modifying anti-
rheumatic drugs (DMARDs) or biologics. These may in-
clude subcutaneous atrophy, hypopigmentation and/or
post-injection pain [14,15]. Several inconsistencies have
been highlighted in studies of IACIs such as variable injec-
tion techniques, inclusion criteria, post-injection proce-
dures, outcome measures, and follow-up period [14,16,17].
Previous systematic reviews have been conducted but
they are now outdated and new studies of IACIs have been
published since they were completed. The Cochrane Col-
laboration recommends that systematic reviews are up-
dated biannually, and the most relevant and recent review
was published seven years ago [18]. Two systematic reviewshave been conducted to evaluate the evidence for IACIs in
JIA; one which focused on IACIs for temporomandibular
joint (TMJ) arthritis only [16]; and another which reviewed
studies on lower limb IACIs for children with JIA and/or
adults with rheumatoid arthritis (RA). However, ultimately
they did not include any studies of JIA [17]. The recent sys-
tematic review of IACIs for TMJ arthritis [16] may not be
directly relevant to this work as IACIs administered in the
joints of the lower limb appear to be less efficacious than
those administered in upper limb and non-weight-bearing
joints [19]. Moreover IACIs administered to the knee joints
appear to be more efficacious than those administered to
the small joints in the foot, where the response is less pre-
dictable [19]. Two other reviews of the overall medical
management of JIA adopted systematic approaches to con-
duct their literature search, but their restrictive inclusion
criteria retrieved only two small randomised studies con-
cerning IACIs and only limited conclusions were drawn
[10,20]. One other systematic review attempted to appraise
the evidence for knee joint IACIs for a range of arthritis
conditions including JIA, osteoarthritis (OA) and RA [21].
However, methodological problems were identified with
this review including a single joint focus (knee), adult arth-
ritis predominance for studies included, and violations of
the detailed inclusion criteria. Narrative reviews have also
been conducted and have provided useful summaries of the
literature concerning IACIs in JIA [14,22]. However, such
reviews are often reinforced with the authors’ expert opin-
ions and clinical experience and as a result may be vulner-
able to bias [23].
Most research concerning IACIs efficacy to date ap-
pears to focus predominantly on the knee joint only, or
a combination of several joints which differ in terms of
anatomical complexity, and may include weight-bearing/
non-weight-bearing joints which could impact on IACI ef-
ficacy. The reviews which have been published to date fail
to account for the efficacy of IACIs for synovitis relief in
other important lower limb joints, and thus the findings
and conclusions drawn from these reviews are not neces-
sarily generalizable. Lastly, it should be noted that stand-
ard clinical practice has changed in recent years with a
greater emphasis being placed on image-guidance to aid
the administration of intra-articular injection therapies
[24-26]. This advancement of clinical practice may have
led to improvements in the effectiveness of IACIs on the
basis of improved steroid placement accuracy and thus
fewer reports of adverse events [24-26]. The emergence
of further evidence, introduction of new technologies
and changing clinical practices has raised important
new questions concerning lower limb IACI efficacy in
JIA. Accordingly, the aim of this review is to systematic-
ally identify and critically evaluate the clinical effective-
ness of IACIs administered to joints of the lower limb
in people with JIA.
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Search strategy
A detailed electronic database search of the literature was
performed using the following databases: Medline,
Embase, CINAHL, AMED, PEDro, the Cochrane Library,
and TRIP. Reference lists of eligible studies identified by
the electronic database search were searched by hand to
identify studies not initially found in the electronic search.
Personal reference lists of the reviewers were also hand
searched to identify any studies known to the reviewers
that may not have been identified by the initial search
strategy. The following search terms ‘juvenile idiopathic
arthritis’, ‘lower limb’, ‘knee’, ‘ankle’, ‘foot’, and ‘intra-articular
steroid injections’ and related synonyms were used to de-
velop a comprehensive pragmatic literature search strategy.
Standard MeSH terms were utilised where possible or an
appropriate text word was adopted. Boolean operators
(such as ‘explode’, ‘OR’, ‘*’, ‘$’ and ‘AND’) were used. The full
search strategy is outlined in Additional file 1.
Study inclusion criteria
Studies included were of a quantitative longitudinal design,
such as randomised controlled trials (RCTs), pseudo-
randomised and non-randomised experimental studies, co-
hort studies, and case-control studies. Studies of single
cases were excluded. Studies reporting children, adolescents
and adults who have JIA were included. Studies of IACIs as
the single primary intervention, in combination with sys-
temic medications, and/or in combination with non-
pharmacological interventions were included. All outcome
measures/variables were subject to analysis. Literature was
limited to full text published articles available in English
due to language barriers of both independent reviewers. No
restriction was imposed on year of publication.
Study abstracts found from the electronic database
search and by hand searching were reviewed for eligibility
based upon the above inclusion criteria. Two independent
reviewers (HJ and KH) selected abstracts which appeared
to meet the inclusion criteria. Full text articles of the se-
lected abstracts were obtained and compared against the
inclusion criteria. The full text, original research articles
meeting the inclusion criteria were assessed for quality.
Quality assessment
Quality assessment was conducted by two independent re-
viewers (HJ and KH) using an adaption of The Cochrane
Collaboration tool for assessing risk of bias as previously
described [18,27]. For randomised studies the internal val-
idity criteria included sequence generation, allocation con-
cealment, blinding of participants and personnel, blinding
of outcome assessment, incomplete outcome data, selective
outcome reporting, and selective outcome reporting.
Whereas for non-randomised studies, adapted criteria were
adopted that did not include criteria that was relevant torandomised studies only. Further internal validity cri-
teria were also included to determine presence of co-
interventions, intervention compliance, and if proper stat-
istical analysis was conducted. External validity criteria
were also included to determine restrictiveness of the in-
clusion and exclusion criteria, and to determine if the
sample population was representative of the general popu-
lation with JIA. For a study to achieve a high quality score
overall, all included domains had to be scored independ-
ently as high quality by both reviewers. A study that was
independently rated with ≥1 domain scored as low quality
was rated as low quality overall. Any disagreement was re-
solved by a third reviewer (GJH).Data extraction/evidence grading
The data extraction/evidence grading system was agreed
upon by the co-authors a priori and is outlined as follows.
Due to a lack of multiple RCTs for specific outcomes mea-
sures, meta-analysis was not possible and as such qualita-
tive data synthesis was conducted. Once extracted data
was analysed and synthesised, an evidence rating was
assigned according to previously published criteria [28]
(Table 1). Once studies were rated for quality, they were
grouped according to the outcomes measured and then
the evidence grading system was adopted to assign levels
of evidence for each outcome. This evidence grading cri-
teria considers both quality and quantity of studies as well
as the consistency of the findings for each outcome [28].Results
Using the detailed search strategy, a total of 568 articles
were retrieved. The inclusion criteria were met by
twenty-one studies (see Figure 1), and a description of
each study is presented in Table 2. The majority of the
studies were observational in nature, with only one
RCT identified for inclusion. Therefore, meta-analyses
were not possible as were originally intended. One study
had high quality internal validity and twenty had low
quality internal validity. Nine studies had high quality
external validity and twelve had low quality external val-
idity. There were no studies with both high quality in-
ternal and external validity (Table 3). From the assessed
studies, nine outcome domains were identified which
included tenderness/pain, swelling, synovitis, effusion,
hyperthermia, sustained ‘clinical response’, joint range of
motion (ROM), length discrepancy (leg length discrep-
ancy or joint circumference), and imaging detectable
outcomes. Leg length discrepancy (LLD) was defined as
unequal length of the lower limb from the knee distally, as
a result of knee synovitis and/or tibial growth distur-
bances. Qualitative syntheses of results are outlined
below and presented in Table 4.
Table 1 Evidence rating criteria (adapted from Ariens et al, 2000 [28])
Strong At least 2 studies of high quality with consistent findings (agreement of >75% of studies)
Moderate 1 high quality study and at least 2 low-quality studies with consistent findings (agreement of >75% of studies)
Weak At least 2 low-quality studies with consistent findings (agreement of >75% of studies)
Inconclusive Insufficient and/or conflicting studies
Figure 1 Flow chart of literature search for IACI use in children with JIA in the lower limb (PRISMA diagram adapted from Moher et al,
2009 [29]).
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Table 2 Description of included studies
Author, year Study
type
Participant description No. entered/
completed study





RCT Fulfilment of EULAR/WHO
Oslo Criteria for JCA.
23/23 (23 knees) 1, 3, 7 and 42 days TH in 11/23 Knee Joint Circumference (cm);
Knee Joint Flexion (degrees).
BM in 12/23
(Dose not recorded)




OBS Failure to respond to NSAIDs
with/without slow acting
anti-inflammatories.
24/24 (30 knee joints) 3, 6, 9, 12 and 24 months. MA 1 mg/kg/joint mixed with 1 cc
1% lidocaine without adrenaline.
Sustained Clinical Response:
‘Active Inflammation’ (joint
effusion and heat and
tenderness/pain with/without
correction of deformity)Co-interventions: 10/24: MTX
(10 mg/kg/wk), 24/24: Naproxen
(10-20 mg/kg/day), 24/24: NSAIDs,
11/24: Prednisolone (0.25 mg/kg/day)
Post-injection: Immobilisation 24




OBS <16 yrs of age at onset of
chronic arthritis 29/40
pauciarticular onset JRA
40/40 (53 knees) 4
patients lost to follow-up.






Post-injection: Not specified Inflammation’(Joint effusion
and heat and tenderness,
with or without complete
correction of deformity)6/40 psoriatic arthritis
Co-interventions: 100%- acetylsalicylic acid
for at least 3 months; 30%- 1 NSAID;
22.5%- 2 NSAIDs; 20%-≥ 3 NSAIDs;
3 patients previously on oral prednisone;
1 patient on hydroxychloroquine; 4 patients
prior corticosteroid injection (other than TH);




OBS Definitive JIA diagnosis based on criteria. 38/38 (55 STJ injections) 1-30 weeks
(median = 6 weeks)
TH in 13/38TA in 24/38 Sustained Clinical Response:
STJ Eversion/Inversion and
pain and gait abnormalitiesDecreased foot inversion or
eversion on physical examination
(Medication and dose not
recorded in 1/39 injection)
Co-interventions: 14/38: MTX, 3/38:
TNF-alpha inhibitor, 3/38: TNF-alpha
inhibitor and MTX.
TA used when TH was
commercially unavailable.
Post-injection: Non-weight bearing




OBS Clinical signs of STJ inflammation 38/38; 24/38 2-3 months 0.5-1 ml, 20 mg/ml TH Increased STJ
Referral for image-guided IACI. single STJ; 4/38 bilateral
STJ; 3/38 subsequent
contra-lateral STJ; 7/38 at
least one repeated STJ.
(active disease) 6 months
(without active disease)
Post-injection: Not specified. inversion and eversion: Normal
ROM, without pain and limping
Co-interventions: Not specified.

















Table 2 Description of included studies (Continued)
Earley
et al., [33]
TH 20 mg for children weighing
<20 kg (63 knees) OR for children
>20 mg 40 mg (20 knees)
Sustained Clinical Response:
Soft tissue swelling and joint
effusion and degree of flexion
contracture and degree of
valgus deformity.
Painful swollen knee with poor function.
Not respondent to at least 3
months of conventional treatment.
Post-injection: Not specified.
Co-interventions: All patients were on
at least one NSAID and physiotherapy




OBS JRA diagnosis based on ACR criteria. 85/85 (51/99 received TH
and 48/99 received TA; 14
patients received both)
2 weeks then every 3
months for a minimum
for 15 months.
TH: 40 mg (knee), 30 mg (ankle). Sustained Clinical Response:
Non-bony swelling and
(if no swelling) limitation
ROM pain on motion or
joint tenderness.
Co-interventions: TH group: 33/51
NSAIDs; 16/51 MTX; 9/51 sulfasalzine;
3/51 prednisone + etanercept;
14/51 no medication.
TA: 80 mg (knee), 60 mg (ankles)
Post injection: Minimal activity
for 24 hrs post-injection.
TA group: 33/51 NSAIDs; 12/51 MTX;
2/51 sulfasalazine; 4/51 etanercept;
2/51 prednisone; 2/51 leflunomide;
15/51 no medication.
Eich et al., [35] OBS JCA diagnosis based on
EULAR criteria.
15/15 (11 knees) Clinical and US assessment:
1 week and 1 month
MRI: 1 month
TH: 40 mg (knee) Pain
Post-injection: Not specified.






Popliteal cyst in affected knee.
Leg-length discrepancy
With/without complete
deformity correction. MRI: Joint effusion










Cate et al., [36]
OBS Type 1 pauciarticular JCA. 21/21 (27 knees) 6 months TA: 20 mg in children weighing
>20 kg with 1 ml lignocaine.
Sustained Clinical Response:
swelling and synovial fluid
and no increased temperature.Chronic arthritis in ≥1 knee.





















Table 2 Description of included studies (Continued)
Co-interventions: 81% used splints




flexed and extended several
times to distribute drug. No
advice regarding activity levels.
Honkanen
et al., [37]




presence of ‘symptoms’With/without previous IACI.
Co-interventions: 100% on NSAID
agents and regular physiotherapy,
17/79 on hydroxychloroquine,
sodium aurothiomalate or auranofin
(slow-acting antirheumatics), 5/79 on
alternate day glucocorticoid therapy.
TH: in 34/79 (mean
dose 0.7 mg/kg)
Post-injection: Non- weight
bearing for 24 hrs.
Huppertz
et al., [38]
OBS Children with chronic arthritis,
not responding to NSAIDs.
21/21(18 knees, 2 ankles) 7, 13 weeks Knees: 1 mg/kg TH with
20 mg min dose and
60 mg maximum dose.
Joint Swelling
Co-interventions: Not pre-specified.
After 13 weeks, 10/21 had been
treated with concomitant NSAIDs
and 5/21 received chloroquine.
Effusion
Ankle: “a lower dose”




OBS JIA diagnosis based on ILR criteria. 30/30 (40 ankle regions) 4 weeks TA 40 mg/ml Pain
Post-injection: Not specified. US: Synovial hypertrophy
Synovial
Active disease.




23% with MTX and biologics
(3 etanercept, 2 adalimumab,










TH: 1 mg/kg (maximum 40 mg) Sustained Clinical
Response: ‘Clinical
signs of inflammation’Failure to respond to 2
months NSAIDs.
Post-injection: Advised to
keep child at home for first
24 hrs and to avoid physical
exertion and carrying weights.Relapse after full remission period.
Co-interventions: NSAID use was
discontinued in all patients at
time of local treatment
Marti
et al., [19]
OBS JIA patients who received
injections and follow
up as in patients.
60/60 (108 knees; 29
ankles, 5 STJ and 3
midfoot)
Knee: 1-69 months,




TH: 40 mg (knee, shoulder
and hips); 20 mg (wrist,
elbow, ankle and STJ);








TA: 80 mg (knee, shoulder and
hips); 40 mg (wrist, elbow, ankle

















Table 2 Description of included studies (Continued)
Children with a body weight
20-40 kg received 75% of these
doses. Children with body weight
<20 kg received 50% of these doses.
Post-injection: Advised to keep
injected joint as quiet as possible
for 24 hrs post-injection.
Papadopoulou
et al., [40]
OBS Diagnosis JIA based on ILR criteria. 220/220 (186 knees, 168
ankles, 67 STJ, 14 MTJ
and 14 IPJ)
6 months TH: 1 mg/kg (maximum 40 mg)
in knee & hips; 0.75 mg/kg
(maximum 30 mg) in ankles.
Synovitis
MA: 20-40 mg in STJ & intertarsal
joints; 5-10 mg in smaller
foot joints.
Post-injection: Avoid activity
or weight bearing for 24
hrs post-injection.
Previous IACIs with minimum
follow-up of 6 months.
Co-interventions: 61.8% of patients
received systemic medications
including: MTX (56.8%),




OBS JIA diagnosis. 94/94 (66/94- unilateral
knee 28/94 bilateral
knees)
6 months TH: 1 mg/kg (maximum




Initial injection between Feb
1996 and June 1990.
Co-interventions: 57% on NSAIDs,
24% on NSAIDs and “2nd line drugs”





OBS Children with JIA presenting
as painful swollen ankles.




Co-interventions: Not Specified Post-injection: Not specified. MRI: Pannus
Sherry
et al., [43]
OBS Pauciarticular JCA from ACR criteria. 16/16 (15 knees and 6
ankles)
Mean follow-up University of
Washington group: 42 months
(SD +/- 11).
University of Washington
Group: 20 mg TH within
2 months of diagnosis.
Leg Length Discrepancy (cm)
<7 years at diagnosis.
Reviewed at rheumatology centres
at University of Washington or
North Carolina (University of
North Carolina/Duke University)
North Carolina group:
46 months (SD +/- 15)
North Carolina Group: No IACI. Thigh circumference
discrepancy (cm)
Co-interventions: University of Washington
Group: 25% on DMARD therapy, 44% with
physical therapy evaluation, 31% with splints,
0% with shoe lifts North Carolina Group: 21%


















Table 2 Description of included studies (Continued)
therapy evaluation, 43% with
splints, 50% with shoe lifts
Sornay-Soares
et al., [44]
OBS Children meeting the 1997
Durban criteria for JIA with
knee involvement.
8/8 (13 knees) 6 months, 12 months Joint lavage using 2 needles and
0.5-1.51 ml saline. Followed by
one vial of TH, except in 2 knees




Co-interventions: 6/8 on NSAIDs,
5/8 on MTX, 1/8 on Azathioprine,
2/8 on Cyclosporine
Post-injection: Knees were
taped and advised to rest for
24 hrs, keeping in extension
with walking crutches. Ice packs
could be used for pain relief.
Verma
et al., [45]
OBS Diagnosis of unresponsive
oligoarticular/polyarticular JIA.
13/13 (13 knees and 3
ankles) 3 patients were
lost to follow-up at 6
months due to
uncontrolled arthritis.
6, 12 weeks. TA (0.5-1 ml, 20-40 mg). Mid-leg circumference (cm)
Joint swelling/effusion, limitation
of ROM, tenderness, pain, warmth.
4 children were lost to
follow-up at 12 months.
Post-injection: Reduced
movement for 24 hrs.










1, 3, 6, 9, 12, 18
and 24 months
TH: 42 patients treated;








1 mg/kg (>40 mg)
(Availability issues
of TH meant TA was
used as an alternative
in some cases).
Received IACIs from Jan








on NSAIDs, 11.4% on MTX
at last 72 hrs post-injection.
TA:51.7% on NSAIDs,
5% on MTX
OB = observational; RCT = randomised controlled trial; JIA = juvenile idiopathic arthritis; JCA = juvenile chronic arthritis; JRA = juvenile rheumatoid arthritis; WHO =World Health Organization; ACR = American College of
Rheumatology; EULAR = European League Against Rheumatism; ILR = International League of Associations for Rheumatology; ROM = range of motion; MTX =methotrexate; IACI(s) = intra-articular corticosteroid injection;
TH = triamcinolone hexacetonide; TA = triamcinolone acetonide; NSAID(s) = Non-steroidal Anti-Inflammatory Drug(s); MA =methylprednisolone acetonide; BM = betamethasone; IACI(s) = intra-articular corticosteroid
injection(s); US = ultrasound; MRI = magnetic imaging resonance; STJ = subtalar joint; MTPJ =metatarsophalangeal joint; IPJ = interphalangeal joint; SD = standard deviation; TNF-alpha = tumour necrosis factor alpha;





































Balogh et al., [30] Low Low Low High Low Low Low Low
Al-wahadneh, [31] N/A N/A Low Low High Low Low Low
Allen et al., [32] N/A N/A Low Low Low High Low High
Beukelman
et al., [26]
N/A N/A Low Low High High Low High
Cahill et al., [25] N/A N/A Low Low Low Low Low Low
Earley et al., [33] N/A N/A Low Low High Low Low Low
Eberhard et al., [34] N/A N/A Low Low High High Low High
Eich et al., [35] N/A N/A High Low Low High Low High
Hertzberger-ten
Cate et al., [36]
N/A N/A Low Low High Low Low Low
Honkanen et al., [37] N/A N/A Low Low High Low Low Low
Huppertz et al., [38] N/A N/A High Low Low Low Low Low
Laurell et al., [24] N/A N/A Low Low Low High Low High
Lepore et al., [39] N/A N/A Low Low Low Low Low Low
Marti et al., [19] N/A N/A Low Low Low High Low High
Papadopoulou
et al., [40]
N/A N/A Low High High High Low High
Ravelli et al., [41] N/A N/A Low Low Low High Low High
Remedios et al., [42] N/A N/A Low Low Low Low Low Low
Sherry et al., [43] N/A N/A Low High High Low Low Low
Sornay-Soares
et al., [44]
N/A N/A Low Low High High Low High
Verma et al., [45] N/A N/A Low Low Low Low Low Low

















Table 4 Qualitative synthesis of results and overview of evidence
Domain Author, year (ref.) Results Adverse effects Level of evidence (specific areas) Level of evidence (for domain)
Tenderness/pain Eich et al, [35] Knee: 0% after 1 month
(no significance value given)
One patient experienced focal
cutaneous atrophy and a possible
ruptured popliteal cyst
Weak evidence for IACIs
decreasing pain in the
knee as 2 studies show
a reduction of pain
Weak evidence for IACIs
decreasing pain in lower
leg joints overall as 3 studies
show a reduction of pain
Huppertz et al, [38] Knee: 33.3% after 7 weeks
(no significance value given)
Not Specified
Laurell et al, [24] Ankle: Pain regression/partial
improvement = 92.5%




in 3 patients at 4 injection sites
Inconclusive due to lack of studies
(No significance value given)
Swelling Eich et al, [35] Knee: 27.3% after 1 month
(no significance value given)
One patient experienced focal
cutaneous atrophy and a possible
ruptured popliteal cyst
Weak evidence for IACIs
decreasing swelling in lower
leg joints overall as 2 studies
show a reduction in swelling
Huppertz et al, [38] Knee: 0% after 7 weeks
(no significance value given)
Not Specified
Synovitis Papadopoulou et al.,
[40]
Number of joints in remission vs. 0.9% of injected joints suffered
from skin hypopigmentation
or subcutaneous atrophy.
Weak evidence for IACIs decreasing
synovitis in the knee, ankle and
STJ as 2 studies for each joint
showed a reduction of synovitis.
Weak evidence for IACIs
decreasing synovitis in lower
leg joints overall as 3 studies
show reduction of synovitis
Number of joints with synovitis
flare: Knee = 79.2% vs. 20.8%
(p < 0.001); Ankle = 54.8% vs.
45.2% (p = 0.14) STJ = 65.5% vs.
34.5% (p < 0.0001); MTPJ = 85.7%
vs. 14.2% (p = 0.008); IPJ = 90.0%
vs. 10.0% (p = 0.0003).
“A few” patients developed
flushing or redness of the
cheeks 24-48 hrs post-injection.
Inconclusive evidence for MTPJ
and IPJ due to lack of studies
Overall mean relapse time 0.5 yrs
(IQR 0.3-1.3 yrs) vs. mean remission
time 0.9 yrs (IQR 0.6-1.9 yrs).
Ravelli et al., [41] Knee: continued resolution
at 6 months = 69%




(no significance value given)
Remedios et al., [42] Clinical synovitis vs. MRI pannus: Not Specified.
Tibiotalar: 84.6% vs. 84.6%; STJ:
23.1% (definite) vs. 46.2%
(no significance value given)
Mean duration of effect (guided
vs. unguided) (weeks): 38.3 vs.
13.9 (no significance value given)
Effusion Huppertz et al, [38] Knee: 13.3% after 7 weeks
(no significance value given)


















Table 4 Qualitative synthesis of results and overview of evidence (Continued)
Hyperthermia Eich et al, [35] Knee: 18.2% after 1 month
(no significance value given)
One patient experienced focal
cutaneous atrophy and a
possible ruptured popliteal cyst




Al-Wahadneh, [31] Knee: 30/30 = 100% maintained
resolution at 3 months
(no significance value given)
1/24 (4%): short-lived pain and
erythema, 2/24 (8%): subcutaneous
atrophy resolved dramatically after
one year, 2/24 (8%): asymptomatic
periarticular calcification.
Weak evidence for IACIs decreasing
clinical signs and symptoms in the
knee, ankle and STJ as 11, 4 and
2 studies respectively showed
sustained clinical response.
Weak evidence for IACIs
decreasing clinical signs
and symptoms in lower leg




midfoot due to lack of studies
Allen et al, [35] Knee: 18/48 = 37.5% relapse at
6 months (no significance
value given)
Subcutaneous fat atrophy at
injection site in one patient.
Beukelman et al, [26] Knee: 1.4 yrs of resolution




STJ: 1.2 yrs of resolution before
relapse (TH + TA) (SD ± 0.9)
Earley et al, [33] Knee: Excellent/Good Outcome:
92.8% vs.
2/23 had areas of subcutaneous
atrophy at injection site.
Poor/Re-injected: 7.2% at 3 months
(No significance value given)
Eberhard et al, [34] Knee Median Relapse (months) Not Specified.
TH: 11.1 +/- 0.81
TA: 7.95 +/- 0.95
(p = 0.0072)
Hertzberger-ten
Cate et al, [36]
Knee: resolution maintained in
70% of knees for >6 months
(No significance value given)
2/21 patients suffered a small
atrophic lesion at the injection site.
1/21 patient suffered a red and
painful knee the day following




Honkanen et al, [37] Knee: overall probability of
sustained clinical response
was higher for TH then MP
after 6-8 weeks (p > 0.0005)
Not Specified.
Laurell et al, [24] Ankle pain Regression/Partial
Improvement = 92.5% (no
specific data included, only
percentages) after 4 weeks
(No significance value given)
Local subcutaneous atrophy
in 3 patients at 4 injection sites.
Lepore et al, [39] Knee: mean remission
time = 13.9 months



















Table 4 Qualitative synthesis of results and overview of evidence (Continued)
(range = 0-54 months)
(no significance value given)
Marti et al, [19] Mean duration of remission
until flare in months (range):
knee = 8.0 (0-27); ankle = 4.5
(0-13); STJ = 3.5 (0-11); midfoot =
1 (0-3) (no significance value given)
Systemic effects of glucocorticoids
in 7 patients (one flushed cheeks,
three increased appetite, three
mood changes).
Mean follow-up time of joints with
ongoing remission in months
(range):knee = 27.2 (1-69);
ankle = 18.2 (1-39); STJ = 13;
midfoot = n/a (no significance
value given)
Local side effects in 12
patients (14 skin atrophies
combined with
hypopigmentation).
Remedios et al., [42] Clinical synovitis vs. MRI pannus: Not Specified.
Tibiotalar: 84.6% vs. 84.6%; STJ:
23.1% (definite) vs. 46.2%
(no significance value given)
Mean duration of effect
(guided vs. unguided)
(weeks): 38.3 vs. 13.9






in 76.9% knees at 6 months
No adverse effects were recorded.
(no significance value given)
Zulian et al., [46] Knee and Ankle: continued
resolution at 6 months
2 patients in each group
developed skin atrophy
at the injection site.
TH: 81.4% 2 patients experienced reversible
apnoea (<20secs duration) during
the induction phase of sedation.TA: 53.3%
(p = 0.001)
Joint ROM Balogh et al., [30] Knee: BM = 0 degree difference
vs. TH = 13 degrees difference
at 42 days (no significance
value given)
Mild skin atrophy in 1/23 who
was injected with TH
Weak evidence for IACIs
increasing ROM in the
knee as 3 studies
show improvement
Weak evidence for IACIs
increasing ROM in lower
leg joints overall as 5
studies show improvement
Eich et al, [35] Knee: 66.7% improvement after
1 month (no significance
value given)
One patient experienced focal
cutaneous atrophy and a
possible ruptured
popliteal cyst
Huppertz et al, [38] Knee: 92.9% improvement
after 7 weeks (no significance
value given)
Not Specified
Laurell et al, [24] Ankle: 95% improvement after
4 weeks
Inconclusive due

















Table 4 Qualitative synthesis of results and overview of evidence (Continued)
Local subcutaneous
atrophy in 3 patients
at 4 injection sites
(No significance value given)
Cahill et al., [25] STJ: 89.5% returned to normal
ROM within 13 weeks
(no significance value given).
Mean duration of improvement =




to lack of studies
Leg length
discrepancy





and a possible ruptured
popliteal cyst
Weak evidence for IACIs
decreasing LLD as 3
studies show reduction
Sherry et al., [43] Mean difference in leg length
for early intervention vs. control:
Not Specified
0% (±0) vs. 1.0% (±1.4) (p = 0.005)
over mean follow up of 4 months
(SD ± 11 months)
Verma et al., [45] Mean Lower Leg Difference





Circumference Balogh et al., [30] Mean Knee Joint
Circumference (cm):
Mild skin atrophy in 1/23




TH = -1.7 after 1, 3, 7 and
42 days (no significance
values given).
Imaging Weak evidence for IACIs decreasing
imaging findings in lower leg joints
overall as 3 studies show improvement
MR imaging Weak evidence for IACIs decreasing
MRI detectable clinical signs and
symptoms as 3 studies show
detectable improvement
Effusion Eich et al., [35] Knee: 36.4% detected by
MRI at 1 week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy
and a possible ruptured
popliteal cyst
Weak evidence for IACIs
decreasing MRI detectable
effusion as 2 studies show
detectable improvement.
Huppertz et al, [38] Knee and Ankle: 40.0% at
7 and 13 weeks (no
significance value given)
Not Specified.
Pannus Eich et al., [35] Knee: 63.6% detected by
MRI at 1 week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy


















Table 4 Qualitative synthesis of results and overview of evidence (Continued)
and a possible ruptured
popliteal cyst
pannus as 3 studies show
detectable improvement.
Huppertz et al, [38] Knee and Ankle: 10.0% at 7
and 13 weeks (no significance
value given)
Not Specified.
Remedios et al., [42] Clinical synovitis vs. MRI pannus: Not Specified.
Tibiotalar: 84.6% vs. 84.6%; STJ:
23.1% (definite) vs. 46.2%
(no significance value given)
Mean duration of effect
(guided vs. unguided)
(weeks): 38.3 vs. 13.9
(no significance value given)
Popliteal cyst Eich et al., [35] Knee: 33.3% detectable
at 1 week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy






Eich et al., [35] Missing outcome data at
1 week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy




Destruction of meniscus Eich et al., [35] 100% (no ligament
destruction reported)
at 1 week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy




Bone marrow oedema Eich et al., [35] None reported at 1
week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy




Avascular necrosis Eich et al., [35] None reported at 1
week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy






Huppertz et al, [38] Knee and Ankle: 20.0%
detectable at 7 and 13
weeks (no significance
value given)
Not Specified. Inconclusive due to
lack of studies
US imaging Weak evidence for IACIs
decreasing US detectable
clinical signs and symptoms




Eich et al., [35] Knee: 100% detectable after
1 week and 1 month





















Table 4 Qualitative synthesis of results and overview of evidence (Continued)
and a possible ruptured
popliteal cyst
Popliteal cyst Eich et al., [35] Knee: 0% detectable after 1
week and 1 month
(no significance value given)
One patient experienced
focal cutaneous atrophy




Synovial hypertrophy Laurell et al., [24] Talocrural joint = 87%
regression vs. 13% no effect
Local subcutaneous
atrophy in 3 patients
at 4 injection sites.
Inconclusive due to
lack of studies
Posterior-STJ = 95% regression
vs. 5% no effect
Midfoot joints = 91%
regression vs. 9% no effect
(no significance value given).
Mean synovial thickness:
statistically significant
difference at 4 weeks
(p < 0.001)




atrophy in 3 patients




normalisation vs. 5% no
normalisation




given) after 4 weeks.
Abbreviations: STJ subtalar joint, SD standard deviation, IACI(s) intra-articular corticosteroid injection(s), TH triamcinolone hexacetonide, TA triamcinolone acetonide, MP methylprednisolone acetate,
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Three observational studies investigated measures of ten-
derness/pain in the lower leg joints, inclusive of the knee
and ankle [24,35,38]. While all studies showed a reduction
in pain after utilising IACIs, no significance values were
given [24,35,38]. A weak level of evidence was found for
IACIs decreasing lower leg tenderness/pain. Weak evi-
dence for IACIs decreasing tenderness/pain was also
found specifically in the knee (2 studies) and inconclusive
evidence in the ankle due to the lack of studies (1 study).
Swelling
Two observational studies investigated a reduction of
swelling in the knee [35,38]. While no significance values
were reported, there was weak evidence of IACIs de-
creasing swelling.
Synovitis
Three observational studies investigated a reduction of
synovitis in lower limb joints inclusive of the knee ankle,
STJ, MTPJ and IPJ [40-42]. Inter-quartile ranges (IQR)
were only available from one study reporting the overall
mean relapse time of 0.5 yrs (IQR 0.3-1.3 yrs) compared
with the mean remission time of 0.9 yrs (IQR 0.6-1.9 yrs)
[40]. No significance values were given for the other stud-
ies [41,42]. A weak level of evidence was found for IACIs
decreasing synovitis in lower leg joints. Specifically, a weak
level of evidence was found for decreasing synovitis in the
knee, ankle and STJ as two studies showed a reduction.
There was inconclusive evidence for all other lower limb
joints including MTPJ and IPJ.
Effusion
Only one observational study investigated a reduction of
effusion in the knee [38] and no significance values were
given. There was inconclusive evidence for IACIs de-
creasing synovitis in the knee due to lack of studies.
Hyperthermia
Only one observational study investigated a reduction of
hyperthermia in the knee [35] and no significance values
were given. There was inconclusive evidence for IACIs
decreasing hyperthermia in the knee due to lack of
studies.
Sustained clinical response
Thirteen observational studies investigated a sustained
clinical response post-injection in the lower leg joints,
inclusive of the knee, ankle and foot [19,24,26,31-34,
36,37,39,42,44,46]. Sustained clinical response included
measures of pain, oedema, erythema and general inflam-
mation, and was determined over periods ranging from 1-
66 months post-injection, depending on joints investigated.
Four studies showed statistically significant sustainedclinical response [26,34,37,46]. Nine studies also found sus-
tained clinical response in relation to duration of improve-
ment and reduction/resolution of pain, inflammation,
limitation of ROM, joint tenderness, swelling, temperature,
joint effusion, deformity, synovitis, contracture and gait ab-
normalities. However, these results were derived from de-
scriptive statistical analyses only [19,24,31-33,36,39,41,44].
Two studies found statistically significant sustained clinical
response in the knee [34,37]. Six studies also found sus-
tained clinical response in the knee. However, no signifi-
cance values were given as data was presented using
descriptive statistics only [31-33,36,39,44]. One study found
statistical significance for the knee and ankle collectively
[46]. Sustained clinical response was also found in three
studies for the ankle [19,24,42], three studies for the STJ
[19,26,42], and one study for the midfoot [19]. However, no
significance values were given. Overall, there was weak evi-
dence for IACIs decreasing clinical signs and symptoms in
lower leg joints as thirteen studies showed a sustained clin-
ical response post-injection.
Joint ranges of motion
One RCT and four observational studies investigated
joint ROM post-injection. The efficacy of IACIs was in-
vestigated for the STJ [25], knee [30,35,38] and ankle
[24]. However, an odds ratio was only reported by one
study for a mean duration of improvement of 1.2 yrs
(SD ±0.9 yrs) [25]. Weak evidence was shown for IACIs
increasing ROM in lower leg joints collectively. The
RCT showed an increase in knee flexion following admin-
istrations of triamcinolone hexacetonide (TH) and beta-
methasone (BM) [30]. TH increased knee flexion more
than BM [43]. Two observational studies also showed im-
provement of knee ROM [35,38] and weak evidence was
found for IACIs increasing ROM in the knee. One obser-
vational study showed increased foot inversion and ever-
sion [25] and ankle joint ROM normalisation/partial
improvement [24]. Overall, there was inconclusive evi-
dence for IACIs improving joint ROM in the STJ and
ankle.
Leg length discrepancy
One RCT and two observational studies investigated
length discrepancies (LLD) [30,43,45]. Two studies specif-
ically investigated LLD [43,45]. While both studies showed
a decrease in the differences between limb length, only
one was tested statistically and achieved statistical signifi-
cance [43]. The other study only used descriptive statistics
[45]. A weak level of evidence was found for decrease in
lower LLD. One study also found a decrease in knee joint
circumference; however, this was not statistically tested
[30]. This particular study demonstrated that there was a
decrease in knee joint circumference with use of TH or
BM [30] but TH had a greater reduction compared to
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ducing knee circumference due to an insufficient number
of studies.
Disease activity outcomes detected by imaging
Four observational studies investigated the ability of im-
aging techniques to detect the efficacy of IACIs on JIA dis-
ease activity [24,35,38,42]. These studies showed IACIs led
to clinical effects on disease activity as detected by im-
aging techniques when compared to clinical assessment.
However, these differences were not compared using infer-
ential statistics. Overall, there was weak evidence for the
use of imaging techniques detecting the effects of IACIs.
Specifically, two studies investigated the effects of IACIs
using MRI to effusion [35,38]. Three studies investigated
the effects of IACIs using MRI to detect pannus [31,34,44].
There was weak evidence for IACIs decreasing MRI detect-
able effusion and pannus. One study investigated MRI for
detecting the effects of IACIs reducing popliteal cysts, de-
struction of articular cartilage/bone, destruction of menis-
cus, bone marrow oedema and avascular necrosis [35]. One
study investigated MRI for detecting the effects of IACIs re-
ducing the uptake of contrast medium [38]. However, there
was inconclusive evidence for these subdomains due to a
lack of studies. Overall, the level of evidence was weak due
to two studies showing the effects of IACIs using MRI.
Two studies investigated the effects of IACS with muscu-
loskeletal ultrasound imaging [24,35]. One study found de-
creases in signs of joint effusion and/or pannus and popliteal
cyst [24], and one study found decreases in signs of synovial
hypertrophy and synovial hyperaemia [35]. Therefore, the
level of evidence assigned was weak for IACIs decreasing
ultrasound detectable signs and symptoms, and inconclusive
evidence for each specific subdomain.
Discussion
Weak levels of evidence were found for IACIs decreasing
tenderness/pain, swelling, synovitis, clinical signs and symp-
toms, increasing joint (ROM) in lower limb joints and med-
ical imaging disease-related outcomes such as joint
effusion, synovial hypertrophy and erosion. Inconclusive
evidence was present for IACIs reducing effusion, hyper-
thermia, LLD and knee circumference. The majority of
studies were low quality observational studies with one low
quality RCT, and as such these conclusions are based upon
weak evidence only. Additionally, the majority of the stud-
ies identified by the search strategy presented results using
descriptive statistics only, leading to uncertainty regarding
the effectiveness of IACIs versus a suitable comparator.
The results of this contemporary review demonstrate
similar issues raised by previous reviews concerning the
lack of conclusive evidence in support of IACIs improv-
ing clinical outcomes [16,17]. The adopted methodology
of the most relevant previous systematic review appearedto be logical in restricting the inclusion criteria to RCTs in
an attempt to increase the quality of evidence retrieved.
However, at the time, there was a lack of published RCTs
available for inclusion in this review and it subsequently
concluded there was insufficient research to ascertain the
effectiveness of IACIs for JIA. Observational studies were
not considered by the authors as part of the inclusion cri-
teria for that review, and as such potentially important
studies were excluded which may have provided at least a
weak level of evidence concerning IACI efficacy. In con-
trast, our review included observational studies and found
weak evidence to suggest that sustained clinical response
and improved joint ROM can be achieved following ad-
ministration of IACIs to the joints of the lower limb in
children with JIA.
A narrative literature review which adopted systematic
search criteria on all medical treatment modalities for JIA
including IACIs has previously been conducted [10]. The
authors concluded there was significant evidence of effi-
cacy for the use of IACIs in persistent oligoarticular JIA
and moderate efficacy of IACIs for the use in polyarticular
JIA based upon the findings of three studies [30,46,47].
However, this was not a true systematic review as the ap-
praisal strategy did not adopt rigorous methods of quality
assessment or evidence grading, and their conclusions
were based solely upon effect sizes greater than 50% of pa-
tients. The lack of evidence grading introduces ambiguity
to the conclusion of such reviews.
Our systematic review has utilised a specific quality as-
sessment criteria with emphasis on the internal and exter-
nal validity of the included studies [18]. Our study showed
that while there was only one observational study with
high internal validity [42], nine observational studies
showed high external validity [19,24,26,32,34,35,40,44,46].
This may be explained by the fact that recruitment was
largely conducted alongside standard practice within
paediatric rheumatology outpatient clinics, thus increasing
the clinical relevance of the results. This external validity
criterion was also necessary to assess whether the study
methodologies were pragmatic, as opposed to explanatory
[48]. The pragmatic nature of these studies meant their
conclusions were more likely to be applicable to the gen-
eral population of children/adolescents with JIA to whom
IACIs may be a possible treatment option.
Due to the lack of multiple RCTs in this area, no meta-
analysis could be conducted. This has implications for fu-
ture research as high quality RCTs and meta-analyses are
necessary to inform evidence-based clinical practice. In-
deed a pragmatic RCT of IACIs versus a suitable com-
parator for the relief of localised synovitis could have
sufficient external validity to inform and influence current
practice and health policy in future. However, it is recog-
nised that several clinical practice guidelines recommend
use of IACIs in spite of the lack of high quality research
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knowledged that a placebo- or sham-control arm for a
parallel trial of IACIs may not be possible due to ethical
restraints surrounding the withholding of standard care. A
contextual problem with the lack of robust RCTs to evalu-
ate IACIs at present exists with regards to recent changes
to the Australian Medicare Benefits Schedule [49]. Evalua-
tions of the cost-effectiveness of interventions are nor-
mally embedded within RCTs. At present, and to the best
of the authors’ knowledge, an evaluation of the cost-
effectiveness of IACIs in JIA has yet to be conducted. This
raises an important issue; because presently people with
arthritic conditions in Australia are potentially required to
self-fund the cost of each individual IACI they receive
[49], and doctors cannot yet provide sufficient guidance
regarding this treatment based on robust evidence of
clinical- and cost-effectiveness.
Two studies are frequently cited in reviews of IACIs in
JIA and clinical practice guidelines to draw conclusions
concerning this intervention [46,47]. These prospective,
randomised studies focus on the comparative efficacy of
commonly used steroid preparations triamcinolone hexa-
cetonide (TH) and triamcinolone acetonide (TA), con-
cluding that TH was superior. However, a major limitation
of these studies was that a non-treatment, placebo, or
sham control arm by which to compare the effects of the
IACI interventions was not possible due to ethical con-
straints. Moreover, participants included were not on
stable medication for an appropriate period prior to enrol-
ment, so both studies were vulnerable to confounding
bias. New evidence has emerged since previous reviews
have been published; however, limitations in these studies
are still evident. The well documented restrictions of the
commercial availability of TH resulted in this preparation
being replaced by TA in at least one study included in this
review [25]. A lack of standardisation of IACI interventions
was identified amongst studies retrieved by our search cri-
teria which may be problematic. Frequently studies do not
describe their injection technique, which can vary between
individual institutes [22]. Moreover, studies included in this
review have utilised varying post-injection management
strategies including physiotherapy rehabilitation [31], immo-
bilisation [31,34], and a period of non-weight-bearing or
avoidance of physical activity [26,37,40,45]. Despite this,
other studies included did not describe a post-injection strat-
egy [24,35,38,42,43]. These approaches appear to lack con-
sensus, and at present there is a lack of evidence available to
support a specific post-injection procedure.
A novel finding from this review was that several studies
employed image-guidance to aid their IACIs [24-26,38,42].
Ultrasonography-guided injections also have been identi-
fied as a useful imaging technique for IACIs as they permit
the real-time guidance of the needle and allow confirmation
of correct deposition of steroid [24,35]. These studiesconcluded the use of imaging techniques ensured correct
needle placement and guided IACIs were superior to stand-
ard ‘blinded’ injection and aspiration techniques. These
studies also raise further questions surrounding image-
guidance concerning whether or not image-guidance can
reduce the rate of complications associated with IACIs. At
present there have been no RCTs comparing guided and
blindly administered IACIs in JIA.
The conclusions from this review contribute to the evi-
dence base in support of current JIA management prac-
tices through aggressive and early intervention to reduce
disease activity [11]. This highlights inconsistencies and
evidence gaps concerning the efficacy of IACIs in JIA. It
also provides valuable additional and contemporary infor-
mation through a robust and systematic approach relative
to previous reviews. While investigating the efficacy of
IACIs, post-injection procedure was included in the study
description as a contextual factor. This did not occur in
previous reviews. Not all studies included a post-injection
technique. Those studies that did include post injection
procedure are described in Table 3. However, the lack of
consistency among the described injection procedures
makes it difficult for comparison to make a consensus.
This is an area which requires further research.
There were a number of limitations for this systematic re-
view that should be acknowledged. Language was limited
to English which is generally not recommended, but is
often difficult to overcome [50]. There were two identified
studies which had to be excluded based on language bar-
riers (Spanish and Russian languages) that could have po-
tentially had an impact on the findings of this review. It is
acknowledged that a number of studies were identified by
hand-searching that were not identified using the detailed
search strategy. The original search strategy was reviewed
to investigate whether or not it was adequate. The minor
problem with the search strategy was subsequently attrib-
uted to an indexing issue within the databases that could
not be overcome by altering the search strategy. However,
in spite of this limitation, the pragmatic nature of the
reviewing strategy permitted important and relevant studies
which met the inclusion criteria to be identified by hand.
Conclusions
In conclusion, there is conflicting and inconclusive evi-
dence for the efficacy of lower limb IACIs for JIA. While
there is enough quantity among the current body of
knowledge to provide weak evidence in some outcome do-
mains for generalised efficacy of IACIs administered to
the lower limb, efficacy for duration of relief of synovitis in
specific lower limb joints remains inconclusive. It is for
this reason we conclude that more high quality studies are
needed to definitively determine the efficacy of lower limb
IACIs for improving outcomes associated with the JIA dis-
ease process.
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